product name Phenoxybenzamine HCl
Description: Phenoxybenzamine HCl (also known as NSC 37448, NCI-c01661) is a non-specific, irreversible alpha antagonist with an IC50 of 550 NM. It is used in the treatment of hypertension, and specifically that caused by pheochromocytoma. It has a slower onset and a longer-lasting effect compared with other a-blockers. It was also the first alpha blocker to be used for treatment of benign prostatic hyperplasia, although it is rarely used today.
References: Br J Urol. 1978 Dec;50(7):551-4.
340.3
Formula
C18H22ClNO.HCl
CAS No.
63-92-3
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: 68 mg/mL (199.8 mM)
Water: 17 mg/mL (50.0 mM)
Ethanol: 68 mg/mL (199.8 mM)
Solubility (In vivo)
Synonyms
NSC 37448, NCI-c01661
other peoduct :References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/19398691
| In Vitro |
In vitro activity: Kinase Assay: Cell Assay: |
|---|---|
| In Vivo | |
| Animal model | |
| Formulation & Dosage | |
| References |
Related Posts
product name Phenoxybenzamine HCl
Description: Phenoxybenzamine HCl (also known as NSC 37448, NCI-c01661) is a non-specific, irreversible alpha antagonist with an IC50 of 550 NM. It is used in the treatment of hypertension, and specifically that caused by pheochromocytoma. It has a slower onset and a longer-lasting effect compared with other a-blockers. It was also the first alpha blocker to be used for treatment of benign prostatic hyperplasia, although it is rarely used today.
References: Br J Urol. 1978 Dec;50(7):551-4.
340.3
Formula
C18H22ClNO.HCl
CAS No.
63-92-3
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: 68 mg/mL (199.8 mM)
Water: 17 mg/mL (50.0 mM)
Ethanol: 68 mg/mL (199.8 mM)
Solubility (In vivo)
Synonyms
NSC 37448, NCI-c01661
other peoduct :References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/19398691
| In Vitro |
In vitro activity: Kinase Assay: Cell Assay: |
|---|---|
| In Vivo | |
| Animal model | |
| Formulation & Dosage | |
| References |